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ABSTRACT
Vascular endothelial growth factor (VEGF) undergoes
alternative splicing to produce both proangiogenic and
antiangiogenic isoforms. Preferential splicing of
proangiogenic VEGF is determined by serine-arginine
protein kinase 1 (SRPK1), which is upregulated in a
number of cancers. In the present study, we aimed to
investigate SRPK1 expression in prostate cancer (PCa)
and its association with cancer progression. SRPK1
expression was assessed using immunohistochemistry of
PCa tissue extracted from radical prostatectomy
specimens of 110 patients. SRPK1 expression was
signiﬁcantly higher in tumour compared with benign
tissue (p<0.00001) and correlated with higher pT stage
(p=0.004), extracapsular extension (p=0.003) and
extracapsular perineural invasion (p=0.008).
Interestingly, the expression did not correlate with
Gleason grade (p=0.21), suggesting that SRPK1
facilitates the development of a tumour
microenvironment that favours growth and invasion
(possibly through stimulating angiogenesis) while having
little bearing on the morphology or function of the
tumour cells themselves.
INTRODUCTION
Prostate cancer (PCa) is the most frequently diag-
nosed cancer in men in the Western world.1 While
in the majority of cases the evolution is mild, an
important number of patients will eventually pro-
gress to the metastatic, castration-resistant form,
resulting in PCa also being the second cause of
death by cancer in men. The most commonly used
classiﬁcations are the clinical TNM (tumour, node
and metastases) staging (based on the presence of
cancer in the prostate, degree of invasiveness in sur-
rounding tissues, involvement of lymph nodes and
the presence of distant metastases)2 and the histo-
pathological Gleason score (based mainly on the
degree of differentiation upon microscopical exam-
ination).3 The most commonly used serum bio-
marker for cancer progression is the
prostate-speciﬁc antigen (PSA). In spite of all these
tools being available, there is still an immense chal-
lenge to better predict prognosis, distinguish
aggressive from indolent forms and therefore guide
therapy. To be able to improve management of
PCa, we need a better understanding of the biology
of this disease.
Angiogenesis is fundamental to tumour growth
and has long been recognised as one of the
hallmarks of cancer.4 Although this process is
known to be important in the pathogenesis of PCa,
trials investigating the use of anti-angiogenic ther-
apies in PCa have thus far proved disappointing.5
Vascular endothelial growth factor (VEGF) is one
of the main inducers of angiogenesis.6 Over a
decade ago it was discovered that VEGF pre-mRNA
undergoes alternative splicing to produce both
proangiogenic and antiangiogenic families of iso-
forms, of which only the former is upregulated in
PCa.7 8 Our group recently described an important
VEGF splicing pathway involving serine/
arginine-rich splicing factor 1 (SRSF1) and its
upstream regulator serine-arginine protein kinase 1
(SRPK1).9 10 In addition to identifying SRPK1 activ-
ity to be responsible for selective upregulation of
proangiogenic VEGF in PCa, we furthermore
described the therapeutic potential of small-
molecule inhibitors of SRPK1.9
SRPK1 is increased in several tumour types
including pancreas, colon and breast, with high
levels of expression correlating with higher disease
grade.11 However, the expression of SRPK1 in
human PCa has not yet been evaluated on a large
scale. The present study therefore aimed to assess
SRPK1 expression in human PCa and correlate this
with clinicopathological parameters. We also
sought to investigate its potential value as a bio-
marker for the prediction of recurrence after
radical prostatectomy.
MATERIALS AND METHODS
Patients and ethics
A cohort of 110 patients that underwent radical
prostatectomy for PCa at our centre during 2010/
2011 were selected from the departmental elec-
tronic database on the basis of available patho-
logical specimens and full clinical follow-up. All
necessary clinical and pathological details were
extracted from the local and/or regional electronic
patient record system. PSA follow-up was harvested
by a separate investigator who was blinded to all
other data. Biochemical recurrence was deﬁned as a
PSA level of ≥0.2 ng/mL, with a subsequent con-
ﬁrmatory level of >0.2 ng/mL in accordance with
the American Urological Association Prostate
Guidelines for Localised Prostate Cancer Update
Panel report and recommendations for a standard
in the reporting of surgical outcomes. Ethical
approval was granted by the National Health
Service National Research Ethics Service
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Committee South West, and all data were anonymised through-
out, with investigators blinded to either clinicopathological or
experimental data as indicated by their involvement in the study.
Tissue sampling
Directly after surgery all radical prostatectomy specimens were
ﬁxed in formaldehyde and transported to the histopathology
laboratory. The outer surface was stained with dye and subse-
quently cut into transverse sections and embedded in parafﬁn to
allow optimal evaluation of surgical margins. H&E slides were
evaluated by a consultant histopathologist with expertise in uro-
logical pathology, and an area of representative tumour identi-
ﬁed and marked. At the time of the study the section containing
representative tumour was recalled from the pathology archives.
The tumour was then sampled using a punch biopsy technique,
along with an area of normal benign prostate glandular tissue,
and re-embedded in parafﬁn. H&E slides of the selected tissue
were then evaluated by a consultant histopathologist with
expertise in urological pathology to ensure that the Gleason
grade of tumour to undergo immunohistochemistry was repre-
sentative of that of the total specimen.
Immunohistochemistry
Immunohistochemistry was performed on 5 μm tissue sections
with a rabbit polyclonal primary antibody against SRPK1
(1:200, HPA016431, Sigma-Aldrich) using the Leica BOND III
fully automated IHC system (Leica Biosystems). Standard manu-
facturer protocols were followed after a 20 min period of heat-
mediated antigen retrieval. The primary antibody was replaced
with standard diluent (Bond Primary Antibody Diluent, Leica
Biosystems) for a set number of samples in each batch of stain-
ing as a negative control. Human vermiform appendix was used
as a positive control for SRPK1.
Staining intensity was scored as negative (0; no staining),
weak (1; only visible at high magniﬁcation), moderate (2; visible
at low magniﬁcation) and strong (3; clearly visible at low magni-
ﬁcation) by two independent assessors, both of whom were
blinded to clinicopathological data. One of the assessors was a
consultant histopathologist with expertise in urological path-
ology. In cases where intensity score differed between assessors,
the sample was re-evaluated and a consensus score allocated.
More speciﬁcally, discrepancy in scoring was encountered in
24.4% of the samples, almost exclusively within one intensity
point of one another. At the time of re-review each slide was
re-examined in detail by both assessors simultaneously and a
consensus score allocated. Both assessors had equal weighting in
these discussions.
Statistical analysis
Differences in SRPK1 expression between benign and PCa tissue
were assessed using the Mann–Whitney rank-sum test. All clini-
copathological correlations with SRPK1 expression were evalu-
ated using Spearman’s rank correlation coefﬁcient since SRPK1
expression is an ordinal variable. Multivariable logistical regres-
sion was used to investigate whether clinicopathological vari-
ables were associated with increased risk of biochemical
recurrence.
RESULTS
Clinicopathological characteristics of the patient cohort are
given in table 1.
Pathological staging of tumours ranged from pT2a-pT3b,
with the majority being pT2c (n=51; 46%). Gleason grade
ranged from 3+3=6 to 4+5=9, with the highest number of
cases being 3+4=7 (n=61; 55%). Mean PSA follow-up was
3.1 years, with 24 patients (22%) experiencing conﬁrmed bio-
chemical recurrence within this period.
Example images of SRPK1 staining intensity and comparison
between benign tissue and PCa are given in ﬁgure 1A–D. The
expression of SRPK1 was signiﬁcantly higher in tumour compared
with benign tissue, with a median difference in expression score of
2 (IQR 1–3, p<0.00001, Mann–Whitney test; ﬁgure 1E).
Correlations between SRPK1 expression and clinicopathologi-
cal parameters are shown in table 2, along with the results of
multivariate logistical regression analysis. SRPK1 expression was
strongly correlated with higher pT stage (correlation coefﬁcient
0.27, p=0.004), the presence of extracapsular extension (correl-
ation coefﬁcient 0.28, p=0.003) and extracapsular perineural
invasion (correlation coefﬁcient 0.25, p=0.008). SRPK1 expres-
sion was not found to be associated with increased risk of bio-
chemical recurrence in our logistical regression model (OR
0.92, 95% CI 0.30 to 2.80), with the only variable identiﬁed as
having a strong association being Gleason grade (OR 3.47, 95%
CI 1.23 to 9.81).
DISCUSSION
This is the ﬁrst study to demonstrate that SRPK1 expression is
signiﬁcantly increased in human PCa compared with benign
tissue, supporting our previously published report that suggests
SRPK1 plays an important role in the pathogenesis of the
disease.9 We found that SRPK1 expression was correlated with
higher pT disease stage, extracapsular perineural invasion and
extracapsular extension. This may indicate that upregulation of
the protein and subsequent promotion of proangiogenic VEGF
splicing is an important event in the PCa progression to a more
Table 1 Clinicopathological details of the patient cohort
Variable Mean (median; range) or n (%)
Age at surgery (years) 64.8 (65.1; 43.7–76.7)
Preoperative PSA (ng/mL) 9.5 (8.8; 1.0–24)
Follow-up time (years) 3.1 (2.8; 0.1–4.1)
Gleason grade
<7 26 (24%)
7 77 (70%)
3+4 61 (55%)
4+3 16 (15%)
>7 7 (6%)
T-stage
pT2 60 (55%)
pT3a 40 (36%)
pT3b 10 (9%)
Extracapsular perineural invasion
Yes 40 (36%)
No 70 (64%)
Extracapsular extension
Yes 48 (44%)
No 61 (56%)
Positive surgical margins
Yes 64 (58%)
No 46 (42%)
Biochemical recurrence
Yes 24 (22%)
No 86 (78%)
PSA, prostate-specific antigen.
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Figure 1 Serine-arginine protein
kinase 1 (SRPK1) expression in benign
and prostate cancer (PCa) tissue.
(A) Benign tissue demonstrating
negative SRPK1 staining intensity
(score 0). (B) PCa demonstrating weak
SRPK1 staining intensity (score 1).
(C) PCa demonstrating moderate
SRPK1 staining intensity (score 2).
(D) PCa demonstrating strong SRPK1
staining intensity (score 3). (E) Box
plot comparing SRPK1 staining
intensity between benign tissue and
PCa. p<0.05 considered statistically
signiﬁcant, calculated using the
Mann–Whitney rank-sum test.
All images acquired using a light
microscope with ×40 objective.
Scale bars are 25 μm.
Table 2 Clinicopathological correlations with SRPK1 expression and multivariate logistical regression analysis of predictive value for
biochemical recurrence
Correlation with SRPK1 score Multivariate logistical regression
Variable
Spearman’s rank
correlation coefficient p Value OR 95% CI p Value
Age at surgery (years) −0.02 0.77 1.10 0.98 to 1.23 0.100
Preoperative PSA (ng/mL) −0.15 0.12 0.97 0.86 to 1.10 0.664
Gleason grade 0.12 0.21 3.47 1.23 to 9.81 0.019
T-stage 0.27 0.004 2.24 0.58 to 8.60 0.239
Extracapsular perineural invasion 0.25 0.008 0.89 0.15 to 5.31 0.902
Extracapsular extension 0.28 0.003 1.07 0.11 to 10.2 0.955
Positive surgical margins 0.08 0.41 2.28 0.67 to 7.75 0.187
Biochemical recurrence 0.08 0.41 NA NA NA
SRPK1 expression* NA NA 0.92 0.30 to 2.80 0.885
*SRPK1 expression converted to a dichotomous variable for purposes of multivariate logistical regression; high (expression score 3) and low (expression scores 0, 1 and 2).
NA, not applicable; PSA, prostate-specific antigen; SRPK1, serine-arginine protein kinase 1.
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advanced phenotype, thereby adding to the body of evidence
supporting SRPK1 as a potential therapeutic target.
Studies evaluating SRPK1 in other tumour types identiﬁed a
positive correlation between expression and grade of disease.11
Interestingly, we did not ﬁnd a signiﬁcant correlation between
SRPK1 expression and Gleason grade in our study cohort. This
may suggest that despite being associated with higher disease
stage, SRPK1 expression is not necessarily increased in high-
grade disease. Indeed, we subjectively observed that those
glands exhibiting highest Gleason grade morphology had rela-
tively low SRPK1 expression, as shown in ﬁgure 2. One explan-
ation for this difference may be that through promoting
proangiogenic VEGF splicing and subsequently boosting new
vessel formation in tumours, increased SRPK1 expression facili-
tates development of a tumour microenvironment that favours
growth and invasion while having little bearing on the morph-
ology or function of the tumour cells themselves.
Our logistical regression analysis did not show an association
between SRPK1 expression and risk of biochemical recurrence
after radical prostatectomy. However, we observed that there
was a subjective increase in the percentage of patients experien-
cing biochemical recurrence as SRPK1 expression increased.
This is suggestive of a potential association and indicates that
the present study may have been underpowered to detect a pre-
dictive effect. Further research using a larger patient cohort is
therefore required before asserting that SRPK1 does not have a
role in the prognostic stratiﬁcation of patients following radical
prostatectomy.
This study is not without limitations. First, only selected
samples of tumour were analysed for SRPK1 expression. It is
well known that PCa is often multifocal and heterogeneous and
so it is possible that the observed staining intensity of the
sample was not representative of other tumour sites within the
prostate.12 Second, the scoring of immunohistochemistry stain-
ing intensity is inherently subjective. We aimed to overcome this
issue through scoring being undertaken by two independent
assessors, one of whom was a consultant urological histopath-
ologist, using a system that has previously been published in the
literature.9
Take home messages
▸ Angiogenesis is important in prostate cancer and depends
on the presence of the pro- and antiangiogenic VEGF-A
splice isoforms.
▸ SRPK1 is a kinase that drives proangiogenic VEGF-A.
▸ SRPK1 expression in prostate cancer is increased compared
to benign tissue.
▸ SRPK1 expression correlates with disease stage and invasion.
▸ SRPK1 expression does not correlate with Gleason score.
Handling editor Cheok Soon Lee
Acknowledgements We wish to thank Annie Smallcombe for technical assistance
in preparation of slides and immunohistochemistry.
Contributors SO, NB, JO and SJH designed the study. NB, AK and JP collected the
data. NP, AJS and SO analysed the data. SO and NB drafted the manuscript. All
authors critically revised the manuscript.
Funding This work was funded by the Biotechnology and Biological Sciences
Research Council (BB/J007293/1). Richard Bright VEGF Research Trust.
Competing interests None declared.
Ethics approval North Bristol NHS Trust.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/
REFERENCES
1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin
2015;65:5–29.
2 Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition
of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol
2010;17:1471–4.
3 Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of
Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic
Carcinoma. Am J Surg Pathol 2005;29:1228–42.
4 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell
2011;144:646–74.
5 Mukherji D, Temraz S, Wehbe D, et al. Angiogenesis and anti-angiogenic therapy in
prostate cancer. Crit Rev Oncol Hematol 2013;87:122–31.
6 Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis.
Cell 2011;146:873–87.
7 Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of
vascular endothelial growth factor, is down-regulated in renal cell carcinoma.
Cancer Res 2002;62:4123–31.
8 Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular
endothelial growth factor splice variant: mechanism of action, in vivo effect on
angiogenesis and endogenous protein expression. Cancer Res 2004;64:7822–35.
Figure 2 Immunohistochemistry staining of high Gleason grade
tumour with low serine-arginine protein kinase 1 (SRPK1) expression.
(A) Gleason grade 4 disease demonstrating weak SRPK1 staining
intensity (score 1). (B) Gleason grade 4 disease demonstrating
moderate SRPK1 staining intensity (score 2). All images taken using a
light microscope with ×40 objective. Scale bars are 25 μm.
174 Bullock N, et al. J Clin Pathol 2016;69:171–175. doi:10.1136/jclinpath-2015-203125
Short report
group.bmj.com on October 19, 2016 - Published by http://jcp.bmj.com/Downloaded from 
9 Mavrou A, Brakspear K, Hamdollah-Zadeh M, et al. Serine-arginine protein kinase 1
(SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate
cancer. Oncogene 2015;34:4311–19.
10 Amin EM, Oltean S, Hua J, et al. WT1 mutants reveal SRPK1 to be a
downstream angiogenesis target by altering VEGF splicing. Cancer Cell
2011;20:768–80.
11 Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is
associated with tumorigenic imbalance in mitogen-activated protein kinase
pathways in breast, colonic, and pancreatic carcinomas. Cancer Res
2007;67:2072–80.
12 Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and
therapeutic implications. Hum Pathol 2010;41:781–93.
Bullock N, et al. J Clin Pathol 2016;69:171–175. doi:10.1136/jclinpath-2015-203125 175
Short report
group.bmj.com on October 19, 2016 - Published by http://jcp.bmj.com/Downloaded from 
disease stage and invasion
in prostate cancer and correlates with
determinant of angiogenesis, is upregulated 
Serine-arginine protein kinase 1 (SRPK1), a
Steve J Harper, Jon Oxley and Sebastian Oltean
Nicholas Bullock, Jonathan Potts, Andrew J Simpkin, Anthony Koupparis,
doi: 10.1136/jclinpath-2015-203125
2015
2016 69: 171-175 originally published online October 23,J Clin Pathol 
 http://jcp.bmj.com/content/69/2/171
Updated information and services can be found at: 
These include:
Material
Supplementary
 C1.html
http://jcp.bmj.com/content/suppl/2015/09/22/jclinpath-2015-203125.D
Supplementary material can be found at: 
References
 #BIBLhttp://jcp.bmj.com/content/69/2/171
This article cites 12 articles, 3 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (164)Urological cancer
 (71)Prostate cancer
 (105)Open access
 (157)JCP Education
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 19, 2016 - Published by http://jcp.bmj.com/Downloaded from 
